No profile data available.
Cogent Biosciences, Inc. (COGT) is a healthcare company in the additional cancer treatment drugs industry, based in Waltham, United States, with about 258 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$328.94 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $5.38 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Cogent Biosciences reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$5.38 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Iovance Biotherapeutics, Inc. (IOVA), CG Oncology, Inc. (CGON), Erasca, Inc. (ERAS), Relay Therapeutics, Inc. (RLAY).